With the recent announcement of continued support from the National Institutes of Health RADx initiative, Oceanit’s ASSURE-19 rapid point-of-need COVID-19 test progress was featured in the news from several local outlets.
Oceanit is focusing on quickly bringing ASSURE-19 to market, organizing manufacturing so that we can provide schools, emergency responders, and airports with a simple saliva test to make high-risk situations safer. This phase of funding and work will help with regulatory compliance and approval, as well as support for accelerating a ‘go to market’ timeline and scale manufacturing.
“We’re going to time (the trials) out with our routine testing in the hospital already and at Island Urgent Care,” Dr. Todd Seto of Queen’s Medical Center said, “so whenever people get the nasal swab testing done routinely as their doctor wants them to, we’ll ask them to provide some saliva also.”
Data captured during tests with The Queen’s Medical Center will be submitted to the FDA as part of an application for Emergency Use Authorization (EUA). At the same time, scaling the manufacturing of ASSURE-19 tests will be a big challenge as Oceanit seeks to setup capabilities locally.
“We are focus on scaling, initially here in Hawaii, and then nationally and globally,” said Patrick Sullivan CEO & Founder of Oceanit. “We see this as beginning of digital medicine here. We can build an industry here, initially manufacturing up to 25,000 tests a day.”
You can read more from the Star Advertiser here: https://bit.ly/3hkTf8m
Hawaii News Now featured Dr. Patrick Sullivan in a short segment as well, which can be viewed here: https://bit.ly/32bMI9K
And finally, Pacific Business News covered the ASSURE-19 progress in an update piece from an earlier article in July: https://bit.ly/32iP5rg
